In a post on the social media site, Herrell reported that the first six patients underwent bladder lesion excision for 11 lesions in total. All cases, conducted on May 12 and 13, proved successful. Dr. Jeremy Teoh of The Chinese University of Hong Kong (CUHK) led the cases as part of the pilot phase of the VIABLE trial.

According to Herrell, who founded the company, too, Teoh is a “world-renowned surgeon and research leader in bladder cancer.” He pioneered the “en-bloc” lesion removal technique for bladder cancer lesions as well, the CEO says.